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Summary In developing countries, Strongyloides stercoralis infection is a common cause of
morbidity and mortality. Death from strongyloidosis can result from hyperinfection or dissemi-
nated disease. Infections due to S. stercoralis are unusual in Saudi Arabia and are usually
diagnosed in immigrants from endemic areas. We report a case in which S. stercoralis was
isolated from the sputum of a patient with Gram-negative sepsis and respiratory failure, and
review the salient features of this disease. A high index of suspicion should be maintained by
clinicians treating patients in endemic areas presenting with new-onset wheezing, acute
respiratory distress and/or Gram-negative sepsis to prevent the serious complications of Stron-
gyloides hyperinfection and dissemination.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
In developing countries of the tropics, subtropics and tem-
perate areas, Strongyloides stercoralis infection is a common
cause of morbidity and mortality. Death from strongyloidosis
is the result of hyperinfection or disseminated disease.
Strongyloidosis hyperinfection is defined as an increase in
the parasite load whereby the rhabditiform larvae penetrate* Corresponding author. Internal Medicine Department, King Fahad
Specialist Hospital, P.O. Box 15215, Dammam 31444, Saudi Arabia.
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doi:10.1016/j.ijid.2008.11.019the bowel mucosa and the organism is confined to the organs
normally involved in the pulmonary autoinfection cycle. On
the other hand, disseminated strongyloidosis is characterized
by the migration of larvae to organs not usually involved in
the normal life-cycle of the parasite, such as the brain and
skin.1 Here, we report a case of pulmonary S. stercoralis
hyperinfection syndrome and review the salient features of
this condition.
Case report
A 29-year-old Filipino male, who had been living in Saudi
Arabia for one year and who was not known to have anyPublished by Elsevier Ltd. All rights reserved.
Figure 2 Sputum Gram stain of the patient, showing the S.
stercoralis larvae.
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a history of gradual onset of right-sided lower back pain for
six months. The pain was not radiating and the patient had no
other constitutional symptoms. Two months after the initial
symptoms, he developed sensory loss in the scrotal area and
one month later he was unable to walk. He also developed
urinary retention, which required Foley catheter insertion.
An MRI of the dorsolumbar spine showed diffuse swelling of
the spinal cord at the cauda equine region with dorsolateral
enhancement at the D12 and L1 levels. A biopsy showed a
grade II astrocytoma. The patient was then referred to our
hospital for further management.
On examination, vitals were within normal range and he
generally looked well. He was in a wheelchair and a Foley
catheter was in place. There was no cranial nerve deficit.
However, he was unable to walk and there was loss of
sensation to touch and pin-prick in the lower half of the
body. Power was zero in the lower limbs, whereas it was
normal in the upper limbs. There were some skin eruptions
on his back, thought to be scratch marks. Cardiovascular,
respiratory and abdominal examinations were normal. The
patient was admitted and was started on dexamethasone
10 mg orally, then 6 mg every six hours for two weeks in a
tapering dose. He developed fever, hematuria, epigastric
pain and constipation one week after admission. He was
initially started on meropenem and later piperacillin-tazo-
bactam. Three days later, he developed cough, shortness of
breath and chest pain. Initial chest X-ray and spiral CTof the
chest were both normal. The cough became intolerable, and
later the patient developed hypotension and desaturation. A
repeat chest X-ray revealed accentuated vascular markings,
but no focal parenchymal lung lesion. He was started on
levofloxacin and cotrimoxazole for possible atypical pneu-
monia and Pneumocystis jirovecii pneumonia. Four days
later, a CT scan of the chest showed bilateral midzonal
and basal reticulonodular infiltrates (Figure 1). Blood cul-
ture grew sensitive Klebsiella pneumoniae and extended-
spectrum b-lactamase (ESBL)-producing Proteus mirabilis.
His HIV and human T-lymphotropic virus-1 (HTLV-1) testsFigure 1 CT scan of the chest scout film, showing bilateral
midzonal and basal reticulonodular infiltrates.were both negative. Sputum Gram stain showed S. stercor-
alis larvae (Figure 2). The patient was started on albenda-
zole 400 mg (PO BID), as ivermectin was not available in the
hospital, and cotrimoxazole was discontinued. At that time,
the white blood cell count was 5.8  109/l, with left shift
and toxic granulation, but there was no eosinophilia. He
deteriorated andwas transferred to the ICU, wheremechan-
ical ventilation was initiated. He was shifted to imipenem
and ivermectin 12 mg per naso-gastric tube daily (once it
became available), instead of levofloxacin and albendazole.
After three days, he was defervescent and a chest X-ray
showed significant improvement; ultimately he was success-
fully extubated. He received a total of one week of iver-
mectin. The patient elected to go back to the Philippines and
was discharged after three weeks of hospitalization on
albendazole 400 mg PO BID for seven days, as the ivermectin
was out of stock in the hospital and he was not taking
steroids.
Discussion
S. stercoralis is an intestinal nematode; its life-cycle starts
with the penetration of the skin by the larvae, which then
spread to the lungs and, after being coughed up, are swal-
lowed and passed into the feces.2 After the initial exposure,
infestation with Strongyloides can persist for many years.
Patients experience chronic infection of the gastrointestinal
tract, with symptoms mimicking those of peptic ulcer dis-
ease, manifesting as nausea, vomiting with epigastric pain,
diarrhea and possible weight loss. Patients will also have long
asymptomatic periods.2,3
Other than the gastrointestinal system, the respiratory
tract is the next most commonly affected system associated
with Strongyloides (Lo¨ffler’s syndrome). It can be associated
with a characteristic rash called larva currens.2,4
Strongyloides is unique in its ability to complete its life-
cycle in humans. A dramatic increase in the burden of the
worms occurs through a cycle of autoinfection. Hyperinfec-
tion which is usually the result of increased filariform larvae
generation (accelerated autoinfection), without the spread
of larvae outside the usual migration pattern (e.g. gastro-
intestinal tract, lungs), occurs due to impaired cellular
immunity that is associated with the use of corticosteroids
e290 M. Shorman, J.A. Al-Tawfiqand other immunosuppressive therapies, malignancy, co-
infections with HTLV-1 and HIV, transplant recipients and
diabetes.3,5,6 However, corticosteroid therapy is the most
important risk factor for the development of hyperinfection
syndrome with strongyloidosis, as occurred in this case. In
addition, astrocytoma grade II is a mild form of cancer; it is
unlikely to cause immunosuppression by itself and thus is not
capable of causing disseminated strongyloidosis. Moreover,
the patient did not receive any chemotherapy to account for
immunosuppression.
Hyperinfection usually presents as acute respiratory fail-
ure, and can be mistaken for asthma exacerbation or even
pulmonary embolism. These clinical findings can be attrib-
uted to the direct invasion of organs by the filariform larvae.
Another presentation can be Gram-negative bacteremia; this
occurs after the migration of larvae through the bowel wall.
Pneumonia and even meningitis can be a consequence of
Gram-negative bacteremia.7—9 The presentation of our
patient was classic, with both respiratory symptoms and
the development of K. pneumoniae bacteremia. However,
the clinical manifestations of S. stercoralis hyperinfection
might vary widely. One of the interesting features of S.
stercoralis hyperinfection is the presence of pruritic linear
streaks of the lower trunk, thighs and buttocks, known as
larva currens1. Both larva currens and Gram-negative menin-
gitis were absent in the current case. The presence of
eosinophilia in peripheral blood is encountered in 70% of
patients with Strongyloides; however, because of the immu-
nosuppression, it is only present 20% of the time with hyper-
infection.5,10 Accordingly, this patient had no eosinophilia at
the time of diagnosis.
Similar to the mode of diagnosis in the present case,
diagnosis of hyperinfection or disseminated disease can be
done by examination of stool, sputum or other body fluids and
tissues, which will typically contain filariform larvae.5,11—14
Serology can also be helpful, as a highly sensitive and specific
ELISA assay can detect both symptomatic and asymptomatic
strongyloidiasis.15,16
Management of S. stercoralis infection includes the aim of
eradication of the infection. In patients with uncomplicated
infection, albendazole, 400 mg orally twice daily for 7 days,
or ivermectin, 200 mg/kg orally once daily for 1—2 days, is
sufficient.17 However, in disseminated disease or hyperinfec-
tion syndrome, therapy relies on prolonged or repeated
courses. Some experts recommend the administration of five
to seven days of ivermectin. Treatment efficacy must be
documented after two weeks, with examination of the stool
or the fluid of the upper small bowel for larvae.5,18,19 In one
case of refractory disseminated strongyloidiasis, combined
albendazole and ivermectin has been successful.20 Antistron-
gyloides antibody titers can also confirm the adequacy of
treatment and need to be repeated after three months.21
Strongyloidiasis hyperinfection syndrome carries a
high mortality approaching 100%; mortality with therapy
can exceed 25%.22,23 Immunosuppressed persons, persons
due to receive steroids or other immunosuppressive
medication, or persons infected with HTLV-1 should be
evaluated for possible strongyloidiasis and treated to pre-
vent the development of hyperinfection or disseminated
strongyloidiasis.22,24
A high index of suspicion should be maintained by clin-
icians treating patients in endemic areas presenting withnew-onset wheezing, acute respiratory distress and/or
Gram-negative sepsis to prevent the serious complications
of Strongyloides
hyperinfection and dissemination.9
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